NKF3
Novel kinase family 3 contains PEAK1 (SgK269) and PEAK2 (SgK223), enzymes better known as pseudopodium-enriched atypical kinases. Both localize to pseudopodia and lamellipodia, where they assemble integrin-dependent signaling complexes; PEAK1 is reported to sustain FAK and Src activation downstream of integrin beta 1 and to modulate ERK signaling, while its catalytic status is debated because key motifs diverge from consensus. Elevated PEAK1 expression has been documented in breast, colon and other carcinomas and is associated with migration, invasion and epithelial-to-mesenchymal transition. The family is therefore studied more as a signaling scaffold than as a drug target, and recombinant PEAK proteins support interaction and phosphoproteomic studies.
-
NKF3 Recombinant Proteins (1)
- Species:
- Source:
Recombinant Protein Expression Service
- Codon Optimization
- Gene Synthesis
- Construction of Expression Vector
- Strain Screening
- Protein Expression
- Purification & QC
- Protein Delivery
- Formula: Human
- Molecular Weight: Sf9 insect cells
The EpCAM/TROP1 protein serves as an important homogeneous interacting molecule that promotes direct contact between intestinal epithelial cells (IEC) and intraepithelial lymphocytes (IEL) in the mucosal epithelium. This feature helps establish an immune barrier against mucosal infections. EpCAM/TROP1 Protein, Human (His-SUMO) is the recombinant human-derived EpCAM/TROP1 protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag.
